Stockhub

InnoPharmax Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

27 September 2022

  • curprev 18:1118:11, 27 September 2022‎ 94.119.64.23 talk‎ 1,315 bytes +1,315‎ Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company's core products include N11005, a prandial oral insulin and GemOral. Its core technology is OralPAS Pro platform, a solid-SMEDDS dosage form composed of peptide drug, solvent, co-solvent, and surfactant adsorbed onto granules by inert excipients. The company of..." Tag: Visual edit: Switched
Retrieved from ‘https://stockhub.co/research/InnoPharmax_Inc.’